Markets:

Overview

News

Currencies

International

Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.260 -0.040 (-3.08%)

Official Closing Price Updated: 8:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

September 19, 2022

By Rachael Green, Benzinga

Via News Direct

NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

September 19, 2022

Learn More about NanoViricides, Inc. by gaining access to the latest research report

Via TheNewswire.com

Monkeypox Is Popping Up In Places It Shouldn't But NanoViricides Says It May Have A Solution ↗

August 10, 2022

More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and...

Via Benzinga

NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

August 09, 2022

Via ACCESSWIRE

Short Volatility Alert: NanoViricides, Inc. ↗

August 05, 2022

On Thursday, shares of NanoViricides, Inc. (NYSE: NNVC) experienced volatile short activity. After the activity, the stock price went up +48.37% to $3.65. The overall sentiment for NNVC has been...

Via Benzinga

NanoViricides Initiates New Drug Development To Combat Monkeypox Virus ↗

August 05, 2022

NanoViricides, Inc. (NYSE American: NNVC) reports that it has begun drug development to combat the monkeypox virus.

Via Benzinga

NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis ↗

May 16, 2022

Via Benzinga

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday ↗

August 05, 2022

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...

Via Benzinga

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session ↗

August 04, 2022

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

August 04, 2022

Good morning! It's time for another dive into the biggest pre-market stock movers as we see what's affecting shares on Thursday!

Via InvestorPlace

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

August 04, 2022

Via ACCESSWIRE

NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants ↗

May 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

30 Stocks Moving In Monday's Mid-Day Session ↗

May 23, 2022

Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday.

Via Benzinga

58 Biggest Movers From Yesterday ↗

May 24, 2022

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.

Via Benzinga

Mid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare ↗

May 23, 2022

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 250 points on Monday.

Via Benzinga

24 Stocks Moving in Monday's Pre-Market Session ↗

May 23, 2022

Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.

Via Benzinga

66 Biggest Movers From Friday ↗

May 23, 2022

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.

Via Benzinga

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗

May 22, 2022

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

Via Benzinga

71 Biggest Movers From Yesterday ↗

May 20, 2022

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation...

Via Benzinga

CDC Looking Into 180 Cases Of Unexplained Pediatric Acute Hepatitis: CNBC ↗

May 19, 2022

The Centers for Disease Control and Prevention is now investigating 180 cases of children who suddenly developed severe hepatitis across 36 states and territories, an increase of 71 cases since the...

Via Benzinga

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

May 17, 2022

SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...

From NanoViricides, Inc.

Via AccessWire

Topics Regulatory Compliance

NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

May 16, 2022

SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...

From NanoViricides, Inc.

Via AccessWire

NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program

April 25, 2022

SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...

From NanoViricides, Inc.

Via AccessWire

Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines ↗

March 07, 2022

Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be...

Via Benzinga

Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach ↗

February 28, 2022

Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended...

Via Benzinga

27 Stocks Moving in Monday's Pre-Market Session ↗

February 28, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) rose 45.4% to $1.00 in pre-market trading after the company reported progress on solid-state polymer battery pack development....

Via Benzinga

NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready

February 15, 2022

SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...

From NanoViricides, Inc.

Via AccessWire

Topics Regulatory Compliance

How Many Boosters Will It Take? A Global Population Beset By Pandemic Fatigue Wants A More Permanent Solution ↗

January 31, 2022

Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts ↗

January 19, 2022

Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. As the threat...

Via Benzinga

NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market ↗

December 20, 2021

Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.